Pet Allergy Treatment Market Size & Share 2026-2035

Pet Allergy Treatment Market Size

The global pet allergy treatment market was valued at USD 2.3 billion in 2025. The market is estimated to grow from USD 2.5 billion in 2026 to USD 4.6 billion in 2035, growing at a CAGR of 7.2% from 2026 to 2035, as per the latest report published by Global Market Insights Inc.

The market is witnessing rapid growth owing to the rising incidence of allergies in pets. According to Banfield Pet Hospital data from 2017-2018, flea allergy prevalence was about 1.8% in dogs and 2% in cats, while environmental allergies affected 3.6% of dogs and 0.4% of cats, with both showing an increasing trend over the past decade. As the number of companion animals rises globally, a large proportion of the pet population, including both dogs and cats, has been diagnosed with allergic conditions such as flea allergies, food and environmental allergens. This growing prevalence of allergic conditions in pets increases the demand for effective treatments to manage these conditions, thereby fostering market growth.

Additionally, as owners increasingly consider pets as a part of their family, the average amount spent per household on pets is rising. For example, an average American pet owner spent USD 1,960 on their pet(s) in 2023. The average pet dog costs USD 143 per month in 2024, while cat ownership costs USD 90.50 per month per cat. As households increase their spending on pets, spending on pet healthcare also rises, which consequently drives the demand for various pharmaceutical products, including pet allergy medications.

The global pet allergy treatment market witnessed steady growth between 2022 and 2024, growing from USD 2 billion in 2022 to around USD 2.2 billion by 2024, reflecting moderate but consistent expansion. This growth was primarily driven by the rising prevalence of allergic conditions in companion animals, including flea, food, and environmental allergies, which significantly increased demand for effective therapeutic solutions. Additionally, increasing awareness among pet owners regarding early diagnosis and treatment, along with improved veterinary access, further supported market expansion. Technological advancements in veterinary medicine, such as the development of immunotherapies and improved diagnostic capabilities, also played a crucial role in enhancing treatment efficacy and boosting adoption.

The goal of pet allergy treatments is to manage and control allergic conditions in pets. These treatments are intended for different forms of allergic conditions, including skin allergies, flea allergies, environmental allergies (dust mites, pollen), and food allergies. Treatment includes the use of antihistamines, corticosteroids, topical medications, and allergy-specific immunotherapy drugs. Key market players in the market include Zoetis, Elanco Animal Health Incorporated, Merck Animal Health, Boehringer Ingelheim International, and Virbac. These companies collectively account for a significant share of the global market and play a critical role in shaping industry growth through innovation and product development.

Pet Allergy Treatment Market Trends

• As per GlobalPET, there are over one billion animals kept as pets worldwide. The number of households with pets in the U.S., Brazil, Europe, and China alone has exceeded half a billion. Also, more than half of the world's families are said to have at least one pet.  Such a high volume of pets increases the demand for various pet care products, thus boosting the market growth.
• In addition, the rapid rise in allergic conditions in pets in recent years has significantly aided in the market growth.
• Different types of allergies in pet animals have become increasingly common, leading to a surge in demand for treatment. In the U.S., allergies in dogs and cats have been rising notably over the past decade. For dogs, environmental allergies have increased by about 30% in the last 10 years, with allergic skin disease being the most common issue observed by veterinarians. Flea allergies have also increased, with a 12.5% rise in dogs and a 67.3% rise in cats over the same period.
• With a rise in awareness among pet owners about the effect of these allergies on pets' overall health and life expectancy, the pet owners are seeking effective therapeutics to manage these allergic conditions.
• The emergence of immunotherapy has become another important trend in the pet allergy treatment market. This can be attributed to the focus on developing long-term treatment solutions. Monoclonal antibody-based treatments, such as Zoetis’ Cytopoint, have transformed the pet allergy treatment landscape. This type of treatment provides long-term relief with fewer side effects.
• Additionally, continued product innovation is evident with approvals like Apoquel chewable in 2023, which has already been used to treat over 13 million dogs in the U.S., highlighting strong adoption of advanced therapies.
• Moreover, growing awareness among pet owners regarding preventive care has enhanced the acceptance of these products, which are crucial for market growth.
• Rapidly growing veterinary infrastructure in emerging economies, availability of advanced drugs for managing allergies, and rising adoption of pet insurance are some other factors that are driving the market growth.

Pet Allergy Treatment Market Analysis

Based on the drug class, the pet allergy treatment market is segmented into antihistamines, corticosteroids, immunotherapy, and other drug classes. The antihistamines segment accounted for the highest market share and was valued at USD 804.5 million in 2025.

• The widespread usage of antihistamines as a first-line treatment for allergic reactions in companion animals is a key factor contributing to their high market share in the market.
• Veterinarians commonly prescribe antihistamines, as these drugs provide prompt relief from allergic signs like pruritus, sneezing, and inflammation.
• In addition, these drugs are known to provide rapid action and are relatively safe.
• Furthermore, antihistamines are easy to administer to different species and sizes of animals as they can be dispensed in several forms such as tablets and liquids, and even injectable forms.
• Moreover, the management of mild to moderate allergic reactions with these medications, combined with their availability without a prescription, enhances product adoption and sales.
• The immunotherapy segment, on the other hand, is anticipated to witness rapid growth at a CAGR of 7.8% over the analysis period, driven by increasing adoption of targeted therapies such as monoclonal antibodies and allergen-specific immunotherapy, which offer improved safety, longer-lasting efficacy, and reduced side effects compared to conventional treatments.

Based on the pet type, the pet allergy treatment market is categorized into dogs, cats, rabbits, and other pet types. The dogs segment dominated the market with 65% market share in 2025.

• The increasing segmental growth is attributed to the rising adoption rate of dogs as companion animals, coupled with growing expenditure on dogs. For instance, in 2021, according to the American Pet Products Association (APPA), 90.5 million families own a pet in the U.S., among which 69 million (over 76%) households own a dog.
• Also, countries in Europe such as U.K, Poland, and France are noted to have some of the highest populations of pet dogs. Thus, the higher adoption rates along with increased spending are expected to propel the segmental growth.
• Further, the incidence of allergic conditions such as atopic dermatitis in the dog population is on the rise and is expected to accelerate growth in the market.
• According to data published in the Journal of Veterinary Medicine in February 2024, atopic dermatitis, a chronic allergic skin condition, is prevalent in dogs, impacting 20-30% of the canine population.
• Lastly, growing disposable income in developing economies and the launch of advanced dog-specific products will further spur segmental growth during the forecast timeframe.

Based on the route of administration, the pet allergy treatment market is categorized into oral, parenteral, and topical. The oral segment dominated the market and is anticipated to reach USD 3 billion by 2035.

• The oral segment holds a high market share in the market due to the ease of administration of these drugs.
• Oral dosage forms such as tablets, chews, and liquids are preferred by pet owners as they are less invasive than other forms, such as injections and are easier to use in a pet's routine. This method of treatment increases compliance, especially for long-term allergy treatment and facilitates consistent treatment.
• In addition, oral dosage forms can be easily incorporated into food, which further increases the adoption rate of these products.
• In addition, the wide range of oral medications tailored to specific conditions of pet allergies, like atopic dermatitis and food allergies, is continuously expanding.
• Pharmaceutical companies are producing more taste-appealing drugs, further supporting their adoption.
• The parenteral segment held the second-highest market share of 20.3% in 2025, owing to the growing use of injectable biologics and immunotherapies that provide faster onset of action and improved compliance in managing chronic pet allergies.

Based on the distribution channel, the pet allergy treatment market is classified into veterinary hospital pharmacies, retail pharmacies, and online pharmacies. In 2025, the veterinary hospital pharmacies segment held the highest market share and is expected to showcase growth at 7.3% CAGR over the analysis period.

• Veterinary hospital pharmacies hold a significant market share in the market due to their direct access to veterinary professionals and the ability to provide specialized medications tailored to individual pet needs.
• These pharmacies are typically equipped with trained professionals who can provide specialized guidance on allergy treatments.
• Additionally, they offer a range of allergy treatments, which are prescribed based on thorough assessments by veterinarians.
• Their ability to provide customized care, combined with the trust pet owners place in veterinary hospitals, drives the growth of this segment.

North America Pet Allergy Treatment

North America pet allergy treatment market held the largest market share of 41.8% in 2025 in the global market, and it is anticipated to expand at a 6.8% CAGR over the forecast period.

• North America holds a strong share in the market due to high pet ownership rates in the region, rapid humanization of pets, high levels of veterinary healthcare spending, and the presence of major industry players such as Zoetis and Elanco.
• The early adoption of advanced treatments such as monoclonal antibodies and immunotherapy also contributes to North America’s high share in the market.
• Additionally, a well-established veterinary infrastructure, high adoption of pet insurance, and high levels of awareness of pet dermatological disorders further support regional market growth.

The U.S. pet allergy treatment market was valued at USD 779.1 million and USD 810.7 million in 2022 and 2023, respectively. The market size reached USD 884.5 million in 2025, growing from USD 845.6 million in 2024.

• High rates of pet ownership in the country, coupled with the availability of advanced treatment options, drive the market growth. The growing humanization of pets in the U.S. also increases spending on veterinary care.
• According to the 2021–2022 National Pet Owners Survey by the American Pet Products Association (APPA), 70% of U.S. households owned at least one type of pet. Additionally, almost 69 million of the U.S. households have at least one dog, and 45.3 million have at least one cat.
• Further, studies report that there has been a 30% increase in allergy cases in dogs over the past 10 years.
• Thus, such a high volume of pets in the country, coupled with a high incidence of allergies in pets, increases the demand for pet allergy treatments.
• Moreover, the U.S. market is further strengthened by the presence of major companies in the region, which ensure a constant supply of advanced and effective therapies for pets.

Europe Pet Allergy Treatment Market

Europe market is anticipated to witness significant growth in the coming years.

• The rising adoption of pet animals and surging expenditure on veterinary care are set to augment the market in Germany.
• Recent reports published by FEDIAF and GlobalPETS reveal that Europe is home to approximately 352 million pets across various species. Cats and dogs dominate the pet population, with 129 million cats and 106 million dogs, respectively.
• Also, the strong growth of veterinary infrastructure in the country, with a well-developed ecosystem of veterinary hospitals, clinics, and pharmacies, gives easy access to pet pharmaceutical products.
• Favorable laws and policies implemented in the region by regulatory authorities further aid in the growth of companies operating in the market.

UK pet allergy treatment market is anticipated to witness considerable growth over the analysis period.

• UK holds a substantial share in the Europe market due to strong culture of pet ownership, advanced veterinary services, and high concern for health issues related to animals.
• As per the PDSA Animal Wellbeing Report 2024, 51% of UK adults own a pet. Of which, 28% of UK adults have a dog - an estimated population of 10.6 million pet dogs, and 24% of adults have a cat - an estimated population of 10.8 million pet cats.
• This large number of companion animals such as dogs and cats create an increasing demand for various pharmaceutical products, including pet allergy treatment medications.
• The market growth is also supported by government initiatives and regulations related to pet care, as well as strict animal health policies.

Asia Pacific Pet Allergy Treatment Market

The Asia Pacific market held a market share of 20.7% in the global market in 2025.

• The market’s growth in the Asia Pacific region is primarily driven by the increasing incidence of allergic conditions in companion animals, particularly dermatological allergies and food sensitivities.
• Additionally, rising disposable incomes across emerging economies such as China and India are encouraging higher spending on pet healthcare and wellness.
• This is further complemented by expanding access to advanced veterinary infrastructure, including specialized clinics, diagnostic services, and modern treatment options, which collectively enhance early diagnosis and effective management of pet allergies.

India pet allergy treatment market is predicted to grow significantly over the forecast period.

• India has a large pet population with over 31 million pet dogs and 2.44 million pet cats. The increasing pet ownership and rising disposable income in the country coupled with high expenditure on pet care will offer lucrative market growth opportunity in the country.
• In addition, rapidly expanding veterinary infrastructure in the country, such as veterinary hospitals, clinics, as well as distribution channels such as retails stores and online platforms, will further enhance the market growth.

Latin America Pet Allergy Treatment Market

Brazil market is anticipated to witness significant growth in the Latin America market.

• Brazil has the third-largest pet population in the world with 160 million pets, of which 60 million are dogs, 30 million cats, and 32 million pet-owning households.
• Such high volume of pets coupled with strong growth in veterinary expenditure is anticipated to foster market growth.
• Additionally, the presence of several international as well as local pet care companies in the country further aid in the market growth.
• Furthermore, the country’s improving veterinary infrastructure is expected to support market growth, with pet allergy treatments becoming more accessible and sought after across urban and rural areas alike.

Middle East and Africa Pet Allergy Treatment Market

Saudi Arabia market is witnessing significant growth potential in the Middle East and Africa market, driven by an increasing pet ownership trend and rising awareness of pet health.

• With the growing pet care industry in the country, demand for effective therapies to treat allergies in pets is on the rise.
• Additionally, the country’s improving healthcare infrastructure and a shift towards specialized veterinary care further contribute to the market's expansion, positioning Saudi Arabia as a key player in the Middle East for  market.
• In addition, rising number of working populations is expected to highly influence Saudi Arabia market growth over the foreseeable future.

Pet Allergy Treatment Market Share

The market is highly competitive, with several key companies striving to develop novel formulations in the market. Several major organizations, local small players, and start-ups are joining the industry competition. Top 5 companies in the market, such as Zoetis, Elanco Animal Health, Merck Animal Health, Virbac, and Boehringer Ingelheim International, account for approximately 58% of the global market share. The major market players implement several strategies to maintain a competitive edge in the market. These players are engaged in strategic acquisitions, mergers, collaborations, partnerships, expansions, and product launches among other strategies.

Additionally, there are several local and regional players operating in the market who are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offerings.

Pet Allergy Treatment Market Companies

Few of the prominent players operating in the pet allergy treatment industry include:

• Antech Diagnostics
• Boehringer Ingelheim International
• Ceva Santé Animale
• Dechra
• Elanco
• IDEXX Laboratories
• Merck Animal Health
• Neogen Corporation
• Nextmune
• PetIQ
• Provetica
• Vetoquinol
• Virbac
• Zoetis

• Zoetis

Zoetis is a key player in animal health, renowned for its extensive portfolio of pet allergy treatments. Notable products include Apoquel and Cytopoint, which are widely used for managing allergic dermatitis in dogs. These products are trusted by veterinarians for managing itch and inflammation caused by allergies. The company’s strong R&D pipeline and global distribution network help maintain its dominant position.

• Boehringer Ingelheim

Boehringer Ingelheim offers a range of allergy treatment products, such as Atopica and Vetadryl, catering to various allergic conditions in pets. It leverages deep scientific expertise to deliver immunomodulatory and antihistamine solutions for pets. The company also invests heavily in innovation to support long-term therapeutic development in veterinary dermatology.

• Elanco

Elanco provides a variety of allergy treatments, including Comfortis and Trifexis, addressing flea allergies and other allergic conditions in pets. The company focuses on companion animal well-being through a combination of parasiticides and anti-allergy solutions. Elanco’s acquisition strategies and product diversification contribute to its growing presence in the allergy segment.

Pet Allergy Treatment Industry News

• In September 2024, Boehringer Ingelheim acquired Saiba Animal Health AG, a company dedicated to developing innovative therapeutic medicines for chronic diseases in pets. Saiba Animal Health’s innovative technology platform uses a first-of-its-kind therapeutic vaccine approach, which is designed to create an immune response, targeting chronic diseases such as allergy, inflammation and pain. This acquisition helped the company to enhance its capabilities in the pet therapeutics sector.
• In September 2024, Elanco Animal Health announced FDA approval and launch of Zenrelia (ilunocitinib tablets), a new oral medication for dogs designed to manage allergic dermatitis and atopic dermatitis. This approval marks a significant advancement in canine dermatology, providing an effective treatment option for pruritus (itching) associated with these conditions in dogs aged one year and older.
• In June 2023, Zoetis Inc. received FDA approval for Apoquel Chewable, a chewable form of oclacitinib designed for the management of pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged twelve months and older. This new formulation represents a significant advancement in veterinary dermatology, as it is the first chewable treatment available in the U.S. for these conditions, which affect a substantial portion of the canine population.

The pet allergy treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Antihistamines
• Corticosteroids
• Immunotherapy
• Other drug classes

Market, By Pet Type

• Dogs
• Cats
• Rabbits
• Other pet types

Market, By Route of Administration

• Oral
• Parenteral
• Topical

Market, By Distribution Channel

• Veterinary hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE